ArticleTherapeutic advances in hematology2026
Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study.
Huishou Fan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.